Ocular Therapeutix OCUL Stock
Ocular Therapeutix Price Chart
Ocular Therapeutix OCUL Financial and Trading Overview
| Ocular Therapeutix stock price | 11.66 USD |
| Previous Close | 11.38 USD |
| Open | 11.56 USD |
| Bid | 11.28 USD x 500 |
| Ask | 11.36 USD x 500 |
| Day's Range | 11.23 - 11.56 USD |
| 52 Week Range | 5.79 - 11.78 USD |
| Volume | 2.13M USD |
| Avg. Volume | 2.23M USD |
| Market Cap | 1.8B USD |
| Beta (5Y Monthly) | 1.406 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.26 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.92 USD |
OCUL Valuation Measures
| Enterprise Value | 1.2B USD |
| Trailing P/E | N/A |
| Forward P/E | -11.107843 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 30.259174 |
| Price/Book (mrq) | 6.7844315 |
| Enterprise Value/Revenue | 20.2 |
| Enterprise Value/EBITDA | -5.969 |
Trading Information
Ocular Therapeutix Stock Price History
| Beta (5Y Monthly) | 1.406 |
| 52-Week Change | 44.14% |
| S&P500 52-Week Change | 13.16% |
| 52 Week High | 11.78 USD |
| 52 Week Low | 5.79 USD |
| 50-Day Moving Average | 8.74 USD |
| 200-Day Moving Average | 8.58 USD |
OCUL Share Statistics
| Avg. Volume (3 month) | 2.23M USD |
| Avg. Daily Volume (10-Days) | 2.46M USD |
| Shares Outstanding | 159.3M |
| Float | 122.34M |
| Short Ratio | 5.95 |
| % Held by Insiders | 3.81% |
| % Held by Institutions | 87.00% |
| Shares Short | 14.42M |
| Short % of Float | 9.09% |
| Short % of Shares Outstanding | 9.05% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | March 31, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -597.46% |
| Gross Margin | -160.39% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.21% |
| Return on Equity (ttm) | -57.19% |
Income Statement
| Revenue (ttm) | 59.65M USD |
| Revenue Per Share (ttm) | 0.36 USD |
| Quarterly Revenue Growth (yoy) | -27.60% |
| Gross Profit (ttm) | -95672000 USD |
| EBITDA | -201834000 USD |
| Net Income Avi to Common (ttm) | -192711008 USD |
| Diluted EPS (ttm) | -1.11 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 349.68M USD |
| Total Cash Per Share (mrq) | 2.2 USD |
| Total Debt (mrq) | 76.22M USD |
| Total Debt/Equity (mrq) | 28.66 USD |
| Current Ratio (mrq) | 10.222 |
| Book Value Per Share (mrq) | 1.67 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -145460992 USD |
| Levered Free Cash Flow (ttm) | -87964376 USD |
Profile of Ocular Therapeutix
| Country | United States |
| State | MA |
| City | Bedford |
| Address | 15 Crosby Drive |
| ZIP | 01730 |
| Phone | 781 357 4000 |
| Website | https://www.ocutx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 274 |
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Q&A For Ocular Therapeutix Stock
What is a current OCUL stock price?
Ocular Therapeutix OCUL stock price today per share is 11.66 USD.
How to purchase Ocular Therapeutix stock?
You can buy OCUL shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ocular Therapeutix?
The stock symbol or ticker of Ocular Therapeutix is OCUL.
Which industry does the Ocular Therapeutix company belong to?
The Ocular Therapeutix industry is Biotechnology.
How many shares does Ocular Therapeutix have in circulation?
The max supply of Ocular Therapeutix shares is 211.9M.
What is Ocular Therapeutix Price to Earnings Ratio (PE Ratio)?
Ocular Therapeutix PE Ratio is now.
What was Ocular Therapeutix earnings per share over the trailing 12 months (TTM)?
Ocular Therapeutix EPS is -1.26 USD over the trailing 12 months.
Which sector does the Ocular Therapeutix company belong to?
The Ocular Therapeutix sector is Healthcare.
Ocular Therapeutix OCUL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 23724.96 USD — |
+0.61
|
9.88B USD — | 23628.82 USD — | 23946.23 USD — | — - | 9.88B USD — |
| US Tech Biotechnology Total Retu XNBI | 5830.62 USD — |
+1.2
|
— — | 5732.51 USD — | 5837.42 USD — | — - | — — |
| US Tech Global Market Composite NQGM | 2309.83 USD — |
+1.58
|
— — | 2282.44 USD — | 2312.75 USD — | — - | — — |
| US Tech Biotechnology NBI | 5366.46 USD — |
+1.2
|
— — | 5276.16 USD — | 5372.71 USD — | — - | — — |
| US Tech Health Care IXHC | 1115.96 USD — |
+0.87
|
— — | 1099.74 USD — | 1117.62 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 29137.78 USD — |
+0.62
|
— — | 29019.72 USD — | 29409.52 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}